Asia Pac Allergy. 2021 Jul;11(3):e36
https://doi.org/10.5415/apallergy.2021.11.e36
pISSN 2233-8276·eISSN 2233-8268

Asia Pacific allergy

Editorial

Preface of the Proceedings of the 34rd Workshop on Eosinophils in Allergy and Related Diseases 2020 (WEA 2020)

Yasuhiro Gon *

Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Received: Jul 23, 2021
Accepted: Jul 28, 2021

***Correspondence to**
Yasuhiro Gon
Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine 30-1 Oyaguchi Kmicho, Itabashi-ku, Tokyo 173-8610, Japan.
Tel: +81-3-3972-8111
Fax: +81-3-3972-2893
Email: gon.yasuhiro@nihon-u.ac.jp

ORCID iDs
Yasuhiro Gon
https://orcid.org/0000-0003-0514-3054

The 34th Workshop on Eosinophils in Allergy and Related Diseases 2020 (WEA 2020) was held on November 3, 2020 as the second wave of coronavirus disease 2019 (COVID-19) was subsiding amidst the onslaught of COVID-19 that had plunged the world into chaos.

This workshop has been held annually for 34 years. It was launched in 1988 by Prof. Sohei Makino (Dokkyo University, Tochigi, Japan) as the chairperson, who was succeeded by Prof. Takeshi Fukuda (Dokkyo University), and it is presently held under the leadership of Prof. Makoto Nagata (Saitama Medical University, Saitama, Japan).

Although the workshop initially focused on the basic biology of eosinophils, recent publications have discussed various aspects of allergies and related diseases more broadly.

This is the second time since 2019 that the Editor-in-Chief of *Asian Pacific Allergy* (AP Allergy) has announced to publish the proceedings of WEA in AP Allergy [1]. This has been conducted by Prof. Yoon-Seok Chang (Seoul National University, Seoul, Korea) with the support of Prof. Ruby Pawankar of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) (Nippon Medical School). We would like to express our deepest gratitude to APAAACI for their cooperation, and we sincerely hope for the development of both parties.

For 34 years, the WEA has been continued without interruption. However, this year, due to COVID-19, we had to postpone the workshop to November (from June) and conduct it as a webinar.

WEA 2020 was held under the supervision of Prof. Yasuhiro Gon (Nihon University School of Medicine, Tokyo, Japan). There were 25 oral presentations, and 3 educational seminars conducted by researchers representing Japan in each field.

The proceedings of WEA2020 include a review article, original articles, and case reports. All of which have been peer-reviewed and accepted through the regular review process of AP Allergy. The review entitled 'Eosinophil-mediated inflammation in the absence of eosinophilia' was contributed by Prof. Ueki et al [2]. In the original articles, Kobayashi et al. [3] reported that mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. Miyauchi et al. [4] reported the effect of Japanese cedar pollen on the effector functions of eosinophils. Koyama et al [5]. reported the inhibitory effect of dexamethasone on murine Th9 cell-mediated nasal eosinophilic inflammation. Ito et al.

[6] reported that L-type amino acid transporter 1 inhibitors suppressed Th2 cell-mediated bronchial hyperresponsiveness independent of eosinophil accumulation, and Uchida et al. [7] reported the use of rush immunotherapy in patients with asthma using dust mite allergens. Furthermore, Kouzaki et al. [8]. reported that interleukin-35 elicited an anti-inflammatory response in the pathogenesis of Japanese cedar pollinosis.

Takeda et al. [9] reported a case of chronic eosinophilic pneumonia involving eosinophil extracellular traps. Furthermore, Sano et al. [10] reported a case of eosinophilic sialadenitis in a patient with severe eosinophilic asthma. Moreover, Nishie et al. [11] reported the case of an adult with food allergy and severe asthma who was successfully treated using omalizumab, and Masaki et al. [12] reported a case with eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab.

We hope that this issue will be of significance to the readers of AP Allergy. We believe that WEA will continue to provide opportunities for exchanging research information between basic and clinical researchers and play an important role in further understanding the pathogenesis of allergic diseases.

WEA 2021 is scheduled to be conducted. We expect an increase in the number of presentations and participants, and especially welcome international delegates. For details, please check the website at http://www.sec-information.net/eosinophils/data/announce.html.

REFERENCES

1. Nagase H. Preface to the Proceedings of the 33rd Workshop on Eosinophils in Allergy and Related Diseases 2019 (WEA 2019). Asia Pac Allergy 2020;10:e22.
PUBMED | CROSSREF
2. Miyabe Y, Kobayashi Y, Fukuchi M, Saga A, Moritoki Y, Saga T, Akuthota P, Ueki S. Eosinophil-mediated inflammation in the absence of eosinophilia. Asia Pac Allergy 2021;11:e30.
CROSSREF
3. Kobayashi K, Nagase H, Sugimoto N, Yamamoto S, Tanaka A, Fukunaga K, Atsuta R, Tagaya E, Hojo M, Gon Y; Sentinel Node Oriented Tailored Approach (SENORITA) Study Group. Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. Asia Pac Allergy 2021;11:e31.
CROSSREF
4. Miyauchi S, Nakagome K, Noguchi T, Kobayashi T, Ueda Y, Soma T, Nagata M. Japanese cedar pollen upregulates the effector functions of eosinophils. Asia Pac Allergy 2021;11:e26.
CROSSREF
5. Koyama T, Miura K, Yamasaki N, Ogata S, Ito D, Saeki M, Hiroi T, Mori A, Kaminuma O. Suppressive effect of dexamethasone on murine Th9 cell-mediated nasal eosinophilic inflammation. Asia Pac Allergy 2021;11:e25.
CROSSREF
6. Ito D, Miura K, Saeki M, Yamasaki N, Ogata S, Koyama T, Hiroi T, Mori A, Endou H, Hayashi K, Kaminuma O. L-type amino acid transporter 1 inhibitor suppresses murine Th2 cell-mediated bronchial hyperresponsiveness independently of eosinophil accumulation. Asia Pac Allergy 2021;11:e33.
CROSSREF
7. Uchida T, Nakagome K, Iemura H, Naito E, Miyauchi S, Uchida Y, Soma T, Nagata M. Clinical evaluation of rush immunotherapy using house dust mite allergen in Japanese asthmatics. Asia Pac Allergy 2021;11:e32.
CROSSREF
8. Kouzaki H, Arai Y, Nakamura K, Murao T, Tojima I, Shimizu S, Yuta A, Shimizu T. Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis. Asia Pac Allergy 2021;11:e34.
CROSSREF

9. Takeda M, Sakamoto S, Ueki S, Miyabe Y, Fukuchi M, Okuda Y, Asano M, Sato K, Nakayama K. Eosinophil extracellular traps in a patient with chronic eosinophilic pneumonia. Asia Pac Allergy 2021;11:e24.
CROSSREF
10. Sano T, Miyata J, Sano A, Ono Y, Tanaka Y, Matsukuma S, Ueki S, Kawana A. Eosinophilic sialoadenitis in a patient with severe asthma: a case report. Asia Pac Allergy 2021;11:e29.
CROSSREF
11. Nishie M, Masaki K, Okuzumi S, Mochimaru T, Kabata H, Miyata J, Takahashi H, Fukunaga K. Successful treatment of a patient with adult food allergy and severe asthma using omalizumab. Asia Pac Allergy 2021;11:e27.
CROSSREF
12. Masaki K, Ueki S, Tanese K, Nagao G, Kanzaki S, Matsuki E, Irie H, Kabata H, Miyata J, Kawada I, Fukunaga K. Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab. Asia Pac Allergy 2021;11:e28.
CROSSREF